Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Trends in the global immuno-oncology landscape

Nature Reviews Drug Discovery volume 17, pages 783–784 (2018)Cite this article

Subjects

An Erratum to this article was published on 26 October 2018

This article has been updated

To inform the cancer immunotherapy community of the advances in the rapidly evolving field, the Cancer Research Institute, a nonprofit group dedicated to research in cancer immunotherapy for more than 65 years, conducted a comprehensive survey of the global immuno-oncology (IO) landscape in September 2017 (Ann. Oncol. 29, 84–89; 2017). One year later, in September 2018, we have conducted another landscape survey. In this report, we compare the two surveys and provide longitudinal analyses of the evolution of the global IO landscape.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Trends in the global IO pipeline.
Figure 2: Trends in IO targets.
Figure 3: Trends in organizations with IO agents in clinical development.

Change history

  • 26 October 2018

    In the original version of Figure 1, the label on the y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.

Author information

Authors and Affiliations

  1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA

    Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey

Authors
  1. Jun Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jill O'Donnell-Tormey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vanessa M. Hubbard-Lucey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

J.O-T. is a paid board member of HemaCare. L. P. is a consultant to Cancer Research Institute and Canadian Cancer Trials Group.

Related links

PowerPoint slides

Supplementary information

Supplementary information

Supplementary Table (XLSX 23 kb)

Supplementary information

Trends of TAA-targeted IO agents in the past year. (PDF 183 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Pearce, L., O'Donnell-Tormey, J. et al. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17, 783–784 (2018). https://doi.org/10.1038/nrd.2018.167

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.167

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing